Bayer's Retinal Pioneers Programme

Established in 2018, Retinal Pioneers is a promotional programme organised and funded by Bayer, designed to contribute towards the evolution of retinal knowledge and catalyse innovation in medical retina. As part of the programme, this Retinal Pioneers Hub provides a source of on-demand, educational resources developed in collaboration with national and international thought leaders in ophthalmology. Materials on this hub are available throughout the year, with new content released quarterly.

Retinal Pioneers Summit (RPS)

The Retinal Pioneers Summit is an annual meeting designed to enable UK ophthalmologists to explore the latest innovations and scientific and clinical advancements in the management of medical retina conditions.

EYLEA (aflibercept) 8 mg: Real-world insights from US and UK clinicians

These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg in clinical practice for licensed indications. Each video includes early experiences and key learnings from real-world cases, designed to aid understanding and help facilitate best practice for EYLEA 8 mg in UK clinical practice.

Key developments relating to EYLEA (aflibercept) 8 mg

Eye on the Horizon podcast series

Episode 6: Beyond the Brain: Navigating Life as Both Neurosurgeon and Patient (NEW!)

Listen to the sixth episode in this podcast series, in which Peter Cackett and guest speaker Henry Marsh (neurosurgeon and author) discuss Henry’s career as a pioneering neurosurgeon and first-hand experience as both doctor and patient. Topics include:

• The qualities that define a great surgeon
• The emotional challenges of working in healthcare and experiencing the healthcare system as a patient
• Key learnings from teaching the next generation of medical professionals

Previous episodes can also be accessed by following the links below.

Challenging cases in medical retina

These case study posters feature challenging scenarios across multiple indications in medical retina, provided by a range of clinicians from across the UK. Each poster includes key information from one or two short case studies and invites you to reflect on the steps that you would follow to manage the same cases.

Resources exploring developments and key principles central to medical retina

Talking head video series with Dr SriniVas Sadda: Advances in imaging technologies

Imaging expert Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA, explores advances in imaging in medical retina in this talking head video series. In each 10-minute video, Dr Sadda provides a detailed overview of a different imaging technology, including its advantages and disadvantages, as well as its practicalities in clinical practice.

Shifting the curve: HCP insights

Abbreviations

AMD, age-related macular degeneration. CBE, Commander of the British Empire. DMO, diabetic macular oedema. FLIO, Fluorescence Lifetime Imaging Ophthalmoscopy. GA, geographic atrophy. GB, Great Britain. HCP, healthcare professional. MDT, multidisciplinary team. nAMD, neovascular age-related macular degeneration. NHS, National Health Service. NI, Northern Ireland. OCT, optical coherence tomography. OCT-A, optical coherence tomography angiography. Q16, every 16 weeks. QR, quick response. RVO, retinal vein occlusion. SEL DESP, South East London Diabetic Eye Screening Programme. T&E, treat-and-extend. UCLA, University of California, Los Angeles. VEGF, vascular endothelial growth factor.

Footnotes

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO). For full details please refer to Summary of Product Characteristics.

*After 3 initial doses, the EYLEA 2 mg treatment interval is extended to 2 months. The treatment interval can then be further extended up to 16 weeks, using proactive T&E dosing.

Prescribing information for EYLEA® (aflibercept) can be found here.